Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Outlook Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2026.
- Period
- the three months ended March 31, 2026
- Result
- preliminary results
Exact text from the filing
On May 13, 2026, the Company announced that, as of March 31, 2026, it had approximately $7.7 million of cash and cash equivalents, which does not include $4.5 million of net proceeds from a registered direct equity offering completed in April 2026. This amount is unaudited and preliminary, is subject to normal quarterly closing processes and accounting review, and does not present all information necessary for an understanding of the Company’s financial condition as of March 31, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Outlook Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $100,000,000 (effective 2026-05-13).
- Action
- entry
- Agreement
- atm program
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- aggregate offering price of up to $100,000,000
- Effective
- 2026-05-13
Exact text from the filing
On May 13, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through H.C. Wainwright as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Outlook Therapeutics, Inc. terminated Prior At-The-Market Sales Agreement with BTIG, LLC valued at at-the-market offering program under which the Company could offer and sell shares of its Common Sto (effective 2026-05-12).
- Action
- termination
- Agreement
- atm program
- Counterparty
- BTIG, LLC
- Value
- at-the-market offering program under which the Company could offer and sell shares of its Common Sto
- Effective
- 2026-05-12
Exact text from the filing
In connection with entering into the Sales Agreement, the Company terminated, effective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”) with BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Prior ATM Program”).
View on SEC.gov